**Supplementary table.** Associated medication of secondary hyperparathyroidism outcome in each of the two groups separately

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  **Month -3** |  **Baseline** |  **Month 3** |  **Month 6** | **P** |
| **Active Vitamin D dose (mcg/week)** **Adherents Cinacalcet (n=18)** **Non-adherents Cinacalcet (n=11)** | 2.12 ± 2.342.64 ± 2.11P=0.540 | 2.41 ± 2.452.64 ± 2.11P=0.779 | 2.76 ± 2.442.82 ± 1.99P=0.952 | 3.12 ± 2.692.64 ± 2.29P=0.629 | NSNS |
| **Phosphate bindings with calcium**  **(pills/d)** **Adherents Cinacalcet (n=18)** **Non-adherents Cinacalcet (n=11)** | 1.53 ± 1.881.36 ± 1.96P=0.735 | 1.82 ± 1.851.45 ± 2.07P=0.557 | 1.88 ± 1.831.55 ± 2.21P=0.665 | 2.00 ± 1.901.55 ± 2.21P=0.567 | NSNS |

ANOVA (repeated measures)